No association of serum PSA with vitamin D or total oxidant-antioxidant capacity in healthy men

References

• Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30:195–200.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101:2371–2490.
   PubMed Web of Science ®Google Scholar
• Gallagher JC. Vitamin D and aging. Endocrinol Metab Clin North Am. 2013;42:319–332.
   PubMed Web of Science ®Google Scholar
• Welsh J. Vitamin D and cancer: integration of cellular biology, molecular mechanisms and animal models. Scand J Clin Lab Invest. 2012;72:103–111.
   Web of Science ®Google Scholar
• Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008;100:796–804.
   PubMed Web of Science ®Google Scholar
• Nomura AM, Stemmermann GN, Lee J, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control. 1998;9:425–432.
   PubMed Web of Science ®Google Scholar
• Baron JA, Beach M, Wallace K, et al. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev. 2005;14:586–589.
   PubMed Web of Science ®Google Scholar
• Gilbert R, Martin RM, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis. Cancer Causes Control. 2011;22:319–340.
   PubMed Web of Science ®Google Scholar
• Gilbert R, Metcalfe C, Fraser WD, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer. 2012;131:1187–1196.
   PubMed Web of Science ®Google Scholar
• Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012;97:2315–2324.
   PubMed Web of Science ®Google Scholar
• Gee J, Bailey H, Kim K, et al. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013;73:970–978.
   PubMed Web of Science ®Google Scholar
• Wagner D, Trudel D, Van der Kwast T, et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab. 2013;98:1498–1507.
   PubMed Web of Science ®Google Scholar
• Khandrika L, Kumar B, Koul S, et al. Oxidative stress in prostate cancer. Cancer Lett. 2009;282:125–136.
   PubMed Web of Science ®Google Scholar
• Paschos A, Pandya R, Duivenvoorden WC, et al. Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics. Prostate Cancer Prostatic Dis. 2013;16:217–225.
   PubMed Web of Science ®Google Scholar
• Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549–1556.
   PubMed Web of Science ®Google Scholar
• Gilbert R, Metcalfe C, Fraser WD, et al. Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. Cancer Causes Control. 2012;23:1865–1873.
   PubMed Web of Science ®Google Scholar
• Sawada K, Kitagawa Y, Ito K, et al. Cumulative risk of developing prostate cancer in men with low (≤2.0 ng/mL) prostate-specific antigen levels: a population-based screening cohort study in Japan. Int J Urol. 2014;21:560–565.
   PubMed Web of Science ®Google Scholar
• Loeb S, Carter HB, Catalona WJ, et al. Baseline prostate-specific antigen testing at a young age. Eur Urol. 2012;61:1–7.
   PubMed Web of Science ®Google Scholar
• Giangreco AA, Vaishnav A, Wagner D, et al. Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer Prev Res (Phila). 2013;6:483–494.
   PubMed Web of Science ®Google Scholar
• Anic GM, Albanes D, Rohrmann S, et al. Association between serum 25-hydroxyvitamin D and serum sex steroid hormones among men in NHANES. Clin Endocrinol (Oxf). 2016;85:258–266.
   PubMed Web of Science ®Google Scholar
• Chandler PD, Giovannucci EL, Scott JB, et al. Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial. Cancer Epidemiol Biomarkers Prev. 2014;23:1944–1947.
   PubMed Web of Science ®Google Scholar
• Park SG, Yeo JK, Cho DY, et al. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. Aging Male. 2018;21:55–59.
   PubMed Web of Science ®Google Scholar
• Peskoe SB, Joshu CE, Rohrmann S, et al. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate. 2015;75:1167–1176.
   PubMed Web of Science ®Google Scholar
• Canguven O, Talib RA, El Ansari W, et al. Vitamin D treatment improves levels of sexual hormones, metabolic parameters and erectile function in middle-aged vitamin D deficient men. Aging Male. 2017;20:9–16.
   PubMed Web of Science ®Google Scholar
• Chin KY, Ima-Nirwana S, Wan Ngah WZ. Vitamin D is significantly associated with total testosterone and sex hormone-binding globulin in Malaysian men. Aging Male. 2015;18:175–179.
   PubMed Web of Science ®Google Scholar
• Kristal AR, Darke AK, Morris JS, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106:456.
   Google Scholar
• Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001–2004. Cancer Epidemiol Biomarkers Prev. 2007;16:70–76.
   PubMed Web of Science ®Google Scholar
• Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006;107:2361–2367.
   PubMed Web of Science ®Google Scholar